Pharmaleaders Visionary
Pharma Entrepreneur 2014 Awardee Dilip Surana led Microlabs
aims $1 billion mark by 2016
Bangalore based Top Pharma
Major Microlabs known as Dolo Maker plans to scale new heights under Dilip
Surana’s Visionary & Commanding Leadership, Dilip Surana to receive
“Visionary Entrepreneur of the Year Award” at Pharma Leaders 2014 Historic Meet
Sunday,7th December 2014, Mumbai, Maharashtra : It is widely believed that the consolidations in the Indian pharma
sector is likely to continue, particularly among generic drug players and will
drive shareholder value going forward.India-based pharmaceutical companies have
majorly been absent from much of the recent M&A activities, partly because
of their healthy growth outlooks. The global pharmaceutical industry will
continue to undergo a pace of rapid consolidation to drive shareholder value;
particularly in the case of companies seeking new growth platforms, against the
backdrop of patent expirations.With many drugs going off patent in the US,
Indian pharma companies would continue to experience strong growth in American
market, indian pharma companies would continue to experience strong growth in
the US over the medium-term. This would be driven by the sizable generic opportunity
(drugs with brand value of $25-30 billion are expected to face generic
competition) over the next 2-3 years.
As one of the recently industrialized nations, India has a fast-growing
economy as well as an ever-expanding, ever-urbanized population, however its
healthcare system still has a lot of potential for development. To Western
readers, analyzing a healthcare system in the East seems daunting. It takes
some of us decades to master an understanding of the healthcare system of our
origin country. Nevertheless, there are several methods to approaching another
country’s system. These include the exposition of some invariant principles
that apply across various contexts, the application of existing frameworks for
healthcare system analysis, appraisal of the major transitions underway in the
country, and an analysis of the country’s public health issues. India faces
challenges in pursuing each of these goals. With regards to cost, at least 70%
of all healthcare is frequently financed out-of-pocket by the population. There
is little health insurance or other forms of risk pooling, little regulation
and accountability of providers, and a predominance of fee-for-service payment,
all of which are associated with high costs. There is also questionable
efficiency of much of the state healthcare system, and a great distrust of the
public sector. Against the backdrop of the above challenges, Pharmaleaders has
lined up top industry experts, Pharma Academia, Ministry Officials, Government
Representative, Policy Makers & Medical Professionals under one platform
both in india & abroad to debate & deliberate the complex issues of the
industry & give a meaningful discussion on the Brand India & Make In
India concept. More than 300 professionals will be participating the mega event
where professionals from Middle East, Africa, Europe, Lation America will also
be attending.The historic 7th Annual Pharmaceutical Leadership Summit &
Business Leadership Awards 2014 to be held in a uniquely positioned full day
program encompassing two themes “Make In India – Healthcare Reforms ,
Insurance,Innovations,Investments & Infrastructure” & Empowering
India’s Developing Healthcare System - Investing the Healthcare Solutions of
Tomorrow in difficult Times at the Sahara Star, Mumbai International Airport in
Mumbai, India, on December,26th , 2014. This
historic Summit is supported by the Government of India at the Centre
& is actively supported by the
Ministry of Health & Family Affairs,
Govt of India, Ministry of Commerce Pharmaceuticals , Government of india &
host of other trade bodies.
Commenting on the Award Selection to Dilip Surana as “Visionary
Entrepreneur of the Year Award” at pharmaleaders 7th Award Night, Satya Brahma, Chairman &
Editor-In-Chief of Network 7 Media Group said “Pharma Leaders™ , asia’s biggest media in
healthcare communications in association with Network 7 Media Group undertook
the gigantic task of identifying the Leader in Healthcare Innovations as it has
been doing for years. The Primary factor that propelled the Jury is to look at
the forward looking vision of the company coupled with the risk taking
abilities & the visionary Leadership of steering the company in the complex
business of healthcare where each day we are witnessing new competition, bigger
challenges & ability to stay ahead of competition. With a modest beginning
as a pharmaceutical distributor in 1973 by Dilip Surana’s late father Shri
G.C.Surana, the meteoric rise of Microlabs as a Leading player in
pharmaceutical business with a formidable basket of top products enjoying the
strong patronage of medical doctors can be attributed to the fact that how
Dilip spearheaded the strategy to make it big. Today Microlab is ranked among the top 20 pharma companies
in the country.Indeed Microlabs has become one of the top 5 pharma players in
the diabetes sector in India. Hailing from a village near Jodhpur in Rajasthan,
the low profile Dilip Surana together with brother Anand Surana have propelled
the growth engine with tremendous speed & dedicated mindset & your
initiatives in the social sector is also a case to reckon with as Dilip’s
efforts to help the marginalized sections of the society is a sign of a true
global Leader. Pharma Leaders™ salute the deep commitment to bring cheers in
the humanity & the visionary commanding Leadership in taking Microlabs to
the crescendo of success & achievements”.
The Award ceremony is scheduled at 07.00 PM on 26th December 2014
onwards at the Grand Jade Room of Hotel sahara Star, Mumbai, India. Like every
year, this will be attended by more than 300 power packed Healthcare Leaders in
all disciple in the glittering award night followed by cocktail & Dinner
Mr. Dilip Surana son of Late Shri G. C. Surana (Founder of Micro Labs
Limited) joined the family business in 1985 at a young age of 21 years,
and rapidly absorbed the nuances of
Corporate Management that grew the company rapidly into a global pharmaceutical
enterprise specializing in life saving medicines. His early years in industry were marked by distinguished
accomplishments and thus steering Micro
Labs among the top ranking companies in the pharma sector. The AWACS ranking
for the company has improved from over 100 in 1985 to 18 as on 2014.
Under his leadership, the company established world-class
state-of-the-art research and manufacturing facilities covering Active
Pharmaceutical Ingredients (APIs) and finished dosage forms as well as
infrastructure for new drug discovery. He instilled
the most stringent quality standards in his pharmaceutical enterprise. As a
result, Micro Labs has to its credit, all the international regulatory
approvals including US FDA, UK MHRA, Australian TGA etc., reflecting the high
standards of quality and regulatory compliance of research and manufacturing
facilities.
Dilip Surana pioneered the
concept of specialty – wise focused divisions in the Indian Pharmaceutical
Industry and established various divisions that cater to special therapeutic
segments in chronic disease management.
Ø Carsyon – Cardicare specialty division in 1994
Ø Synapse – Neurology Psychiatry division in 1995
Ø Vision – Ophthalmology division in 1998
Ø Gratia – Dermatology Division in 1998
Ø Diabetic Task Force Diabetology division in 2005
Ø Foresee – Nephrology Division in 2008
Ø Micro Critical Care - Critical Care Division 2013
He
is a regular participant in various international seminars and summits relating
to Pharma industry. He is instrumental in inducting Senior Pharma veterans in
the company, to bring in the much needed professionalism in the company. Recognizing the dynamism and contribution of Mr. Dilip
Surana to the Pharmaceutical Industry, he has been honored as the ‘Dynamic
Entrepreneur of the year 2010’, honoured as the ‘Great Son of karnataka’ by Governor of Karnataka his
excellency HR Bhardwaj in 2011, honoured as ‘Most Dynamic Entrepreneur of the
Year’ 2013 and ‘Entrepreneur of the year’ 2014.
Micro Labs Limited is a
multi-faceted healthcare organization with a proficient marketing team,
state-of-the-art manufacturing facilities and R&D centres that are at par
with international standards. All this, robustly backed by a strong
distribution network and path-breaking research work has placed us amongst
India’s fast growing transnational healthcare organizations. Under the able
leadership of Mr. Dilip Surana (Chairman & Managing Director) and Mr. Anand
Surana (Director), Micro’s brand portfolio includes some of the topmost brands
in various specialties like Cardiology, Diabetology, Anti-infectives,
Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning
brand highly prescribed for fever management. Micro Labs has been ranked among
top 17 (as per SMSRC July-Aug’14) in prescriptions and 19 in sales (as per
AWACS Sept’14) in India. The group has its presence in over 30 countries, with
ground level operations in 15 countries, exporting all major dosages in every
therapeutic segment. Being one of the leading Indian healthcare providers in
India, Micro Labs aims to be a prominent pharmaceutical player in regulated and
non-regulated markets across the globe.The company is also at the forefront in
social contribution, striving to be a model corporate citizen in terms of
Environmental Protection & Social Initiatives with significant
contributions in the areas of education and health.Micro Labs is poised to achieve
unparalleled status in the global pharmaceutical industry. Backed by a profound
and resolute vision, we now have our eyes set on attaining the $1 billion mark
by 2016.